Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

• Idiopathic inflammatory myopathy, familial autoimmunity in, 400
• IgG
  • antibodies, in neuropsychiatric SLE, 745
  • anti-double-stranded DNA autoantibodies, in arthritis and pneumonitis, 139
  • anti-P autoantibodies, in healthy children, 33
  • autoantibodies, human anticardiolipin, 1026, 1514
• IgG2, anticardiolipin autoantibodies in antiphospholipid syndrome, 1513
• IgM
  • anti-double-stranded DNA autoantibodies, in arthritis and pneumonitis, 139
  • anti-P autoantibodies, in healthy children, 33
  • in RA, rheumatoid factor-producing B cells, 2211
  • Iloprost
    • in Raynaud's phenomenon secondary to SSc, 670
    • in SSc, 559
  • N-iminoethyl-l-lysine (L-NIL), and nitric oxide synthase inhibition in OA, 1275
  • Immune complex
    • factor B in C2-deficient SLE, 427
    • FcγRIIa polymorphisms in SLE, 421
    • SLE erythrocyte-mediated inhibition of uptake of, 613
  • Immunizations, and antigen-specific antibody responses in SLE, 1828
  • Indomethacin
    • chondrocytes and, 1645
    • VLA/VCAM-1-mediated lymphocyte cell adhesion and, 1677
  • Infection
    • hepatitis C, in HIV, 740, 2077
    • hepatitis C virus, and inflammatory myopathy, 1323
    • mycoplasma, in RA and other rheumatic disorders, 754, 756
    • in plasmapheresis-treated SLE, 414
    • procalcitonin in autoimmune disease as marker of, 566
    • Salmonella, adhesion molecules in, 1054
    • staphylococcal, calcifications in, 373
    • streptococcal, HLA associations in poststreptococcal reactive arthritis, 1096
  • Inflammatory bowel disease-associated arthritis, prevalence in United States, 778
  • Inflammatory myopathy
    • hepatitis C virus infection and, 1323
    • idiopathic, 400
    • idiopathic, familial, 710
  • Infliximab, and MTX in RA, 1552
  • Injections, soft tissue and joint, in warfarin sodium-treated patients, 736
  • Insulin-like growth factor 1, in OA, 891
  • Insulin-like growth factor binding protein 5, identification in synoviocytes in RA, 1356
  • Intercellular adhesion molecule 1, on human articular chondrocytes, 1296
  • Interferon-β (IFNβ)
    • inhibition of COMP, 997
    • in RA with multiple sclerosis, 754
  • Interferon-γ (IFNγ)
    • collagen type I production inhibition and, 2039
    • in collagen-induced arthritis, effects of anti-tumor necrosis factor α and cyclosporine, 1806
    • in RA, 48, 306, 1669
    • and tumor necrosis factor α effects on protein in human chondrocytes, 274
  • Interleukin-1 (IL-1)
    • in antigen-induced arthritis, regulation of matrix metalloproteinase-induced neoepitopes, 647
    • with ATP and UTP in RA synovial cells, 246
    • effect of MTX on, 2032 in RA synovial cells, 246
    • on human articular chondrocytes, 1296
    • -induced cartilage oligomeric matrix protein degradation and matrix metalloproteinases, 2143
    • in leukemic arthritis, 1695
    • in murine experimental arthritis, 634
    • nuclear factor [gk]B/p50 activation of distal metalloproteinase-1 promoter, 1987
    • in OA chondrocytes, 2165
    • oncostatin M in cartilage destruction and, 1760
    • paclitaxel inhibition of, 869
    • in RA, modulation of vascular endothelial growth factor, 1258
    • in RA, tumor necrosis factor α induction of interleukin-11 and, 2004
    • in rheumatoid nodules, 1783
  • Interleukin-2 (IL-2), in RA, 48, 1669
  • Interleukin-3 (IL-3), in antiphospholipid syndrome, 224
  • Interleukin-4 (IL-4)
    • matrix metalloproteinase transcription in synovial fibroblasts and, 1398
    • in RA, 48
  • Interleukin-6 (IL-6), collagen-induced arthritis pathogenesis and, 2117
  • Interleukin-8 (IL-8), receptor-binding chemokines in gout, 900
  • Interleukin-10 (IL-10)
    • in RA, 48, 1669
    • in SLE, and promoter polymorphisms, 1091
    • in SLE susceptibility, 596
  • Interleukin-11 (IL-11), in RA, immunoregulation of inflammation by, 1388
  • Interleukin-12 (IL-12)
    • in RA synovial tissue, 306
    • in SLE, production decrease, 838
  • Interleukin-13 (IL-13), in RA synovial tissue, 1669
  • Interleukin-1 receptor (IL-1R)
    • blockade of IL-1 signal transduction, 515
    • in chronic arthritis, 1083
  • Interleukin-1 receptor antagonist (IL-1Ra)
    • in chronic arthritis, 1083
    • collagen-induced arthritis susceptibility and, 1798
    • MTX effect on, 2032
    • treatment of RA, 2196
    • and VDIPEN in antigen-induced arthritis, 647
  • Interstitial lung disease, intravenous pulse CYC for, 1215
  • Interstitial pneumonitis, anti-transfer RNA antibodies in, 1625
  • Intravascular lymphoma, presenting as symmetric polyarthritis, 1127
  • IR501, vaccine in RA, 1919
  • Irradiation, long-term outcome of total lymphoid, in RA, 945, 946, 947
  • Ischemia
    • cranial, giant cell (temporal) arteritis and, 26
    • cranial, risk of irreversible, and inflammatory response, 2088